Burning Rock Biotech Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 60/78 in the Healthcare Providers & Services industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Burning Rock Biotech Ltd's Score
Industry at a Glance
Industry Ranking
60 / 78
Overall Ranking
356 / 4582
Industry
Healthcare Providers & Services
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Burning Rock Biotech Ltd Highlights
StrengthsRisks
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
Growing
The company is in a growing phase, with the latest annual income totaling USD 71.08M.
Undervalued
The company’s latest PE is -13.35, at a low 3-year percentile range.
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
Ticker SymbolBNR
CompanyBurning Rock Biotech Ltd
CEOHan (Yusheng)
Websitehttps://www.brbiotech.com/
FAQs
What is the current price of Burning Rock Biotech Ltd (BNR)?
The current price of Burning Rock Biotech Ltd (BNR) is 23.390.
What is the symbol of Burning Rock Biotech Ltd?
The ticker symbol of Burning Rock Biotech Ltd is BNR.
What is the 52-week high of Burning Rock Biotech Ltd?
The 52-week high of Burning Rock Biotech Ltd is 23.590.
What is the 52-week low of Burning Rock Biotech Ltd?
The 52-week low of Burning Rock Biotech Ltd is 2.180.
What is the market capitalization of Burning Rock Biotech Ltd?
The market capitalization of Burning Rock Biotech Ltd is 211.19M.
What is the net income of Burning Rock Biotech Ltd?
The net income of Burning Rock Biotech Ltd is -346.63M.
Is Burning Rock Biotech Ltd (BNR) currently rated as Buy, Hold, or Sell?
According to analysts, Burning Rock Biotech Ltd (BNR) has an overall rating of --, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Burning Rock Biotech Ltd (BNR)?
The Earnings Per Share (EPS TTM) of Burning Rock Biotech Ltd (BNR) is -1.626.